Illustrative estimate only - not verified by this sponsor. Contact the study team for actual compensation.
This Phase 1, first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CLYM116 in healthy volunteers.
What happens when you apply
Reach out via phone or email to express interest
Brief call to discuss your health history
Medical screening at the research site
Begin your journey in the study
Inclusion Criteria: * Healthy adult males and females aged 18-60 years, inclusive * Body mass index (BMI) between 18 and 32 kg/m² and weight between 45 and 110 kg * Clinically normal medical history, physical exam, ECG, and laboratory results (or abnormalities deemed not clinically significant) * Willing and able to comply with study procedures and provide informed consent * Women of childbearing potential must use highly effective contraception and have negative pregnancy tests * Men must use contraception and refrain from sperm donation for 4 months post-dose * Completion of COVID-19 vaccination according to local guidelines, as well as influenza vaccination (within 12 months) Exclusion Criteria: * Prior treatment with investigational drugs within 30 days or 5 half-lives * Previous or current hypogammaglobulinemia * Current presence of allergic reactions considered clinically significant * Positive tests for HIV, hepatitis B/C, syphilis, or tuberculosis * Tobacco use (\>2 cigarettes/day), alcohol abuse, or drug abuse * Recent live vaccination (within 21 days) or any non-live vaccine (within 14 days)
imaguineapig pulls live data from ClinicalTrials.gov (NIH/NLM).Illustrative estimate only - not verifiedPay estimates are approximate ranges based on study type and are not confirmed by sponsors — actual compensation may differ. Eligibility indicators use limited criteria (age, sex) only. We do not provide medical advice. Always contact the study team directly to confirm compensation, full eligibility, and risks before enrolling.